Work

OP0130 Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: a phase iii randomised, placebo-controlled trial

Year: 2017

Type: conference-abstract

Source: Annals of the Rheumatic Diseases

DOI: 10.1136/annrheumdis-2017-eular.5610

Authors: ME Wechsler, P Akuthota, D Jayne, P Khoury, A Klion, C Langford, PA Merkel, F Moosig, U Specks, MC Cid, R Luqmani, J Brown, S Mallett, R Philipson, SW Yancey, J Steinfeld, PF Weller, G Gleich

Institutions: National Jewish Health, UC San Diego Health System, University of Cambridge, National Institute of Allergy and Infectious Diseases, Cleveland Clinic, University of Pennsylvania, Mayo Clinic, Hospital Clínic de Barcelona, Universitat de Barcelona, University of Oxford, Beth Israel Deaconess Medical Center, University of Utah Hospital

Language: English

Topic: Vasculitis and related conditions

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Eli Lilly and Company, AstraZeneca, Sanofi, Teva Pharmaceutical Industries, National Institutes of Health, Genentech, National Institute of Allergy and Infectious Diseases, NHLBI Division of Intramural Research

Award: G9000315370

OpenAlex ID: W2945916412

Cites:

Cited by: 1

Related to: 10